INmune Bio, Inc.
- INMB
- NASDAQ
- Biotechnology
- Immunotherapy (Innate Immune)
$1.57
Today +0.32%Quote Oct 19, 2026, 01:54 PM UTC
−27.98%over the last month
Max drawdown −32.6%From 1-month high −32.6%3 months −21.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$43.7M
Quote Oct 19
Next earnings
Oct 29
Expected, not confirmed
Analyst target
$22.00
+1296.8% from here
Floor
$1.47
6.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INMBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
21